Arovella Therapeutics Limited (ALA), previously known as Suda Pharmaceuticals Ltd, is a biotechnology company dedicated to advancing its innovative invariant natural killer T (iNKT) cell therapy platform, originally developed in collaboration with Imperial College London. The focus of Arovella lies in pioneering treatments for both blood cancers and solid tumours. Central to their efforts is ALA-101, a groundbreaking product comprising CAR19-iNKT cells. These cells are engineered with a Chimeric Antigen Receptor (CAR) designed specifically to target CD19, a prevalent antigen present on the surface of various cancer types. This pioneering approach holds promising potential in revolutionising cancer therapy through targeted immunotherapy solutions.